Medicine company Eli Lilly and Company (NYSE: LLY) announced on Monday that it has received U.S. Food and Drug Administration Breakthrough Therapy designation for olomorasib as a monotherapy for adults with previously treated advanced pancreatic cancer carrying a KRAS G12C mutation.
The designation is based on preliminary results from the Phase 1/2 LOXO-RAS-20001 study evaluating olomorasib in patients with KRAS G12C-mutant advanced solid tumours, including pancreatic cancer, and is intended to accelerate the drug's development and regulatory review.
Lilly said there are currently no approved therapies specifically targeting KRAS G12C-mutant pancreatic cancer, a rare form of the disease associated with poor outcomes.
Olomorasib is also being evaluated in multiple clinical studies, including the pivotal SUNRAY-01 and SUNRAY-02 trials in KRAS G12C-mutant non-small cell lung cancer.
Coiled Therapeutics doses first patient with optimised AO-252 formulation
CREATE Medicines agrees strategic research collaboration with Australia's Monash University
Ractigen Therapeutics IND application for RAG-1C receives FDA clearance
GlycoNex commences dosing in Phase I trial of GNX1021 in Japan
Datroway approved in EU for first-line metastatic triple-negative breast cancer
Karyopharm reports topline Phase 3 trial results in endometrial cancer
Kaigene and Taisho enter exclusive KG006 licensing agreement in Japan
Pfizer reports positive Phase 3 results for LITFULO in nonsegmental vitiligo
Octapharma to build USD1.5bn critical care manufacturing facility in Rock Hill, SC
Ractigen Therapeutics closes over USD31m financing for project advancement
10x Genomics and Lausanne University Hospital to collaborate on cancer care research
European Commission approves RINVOQ for severe alopecia areata
AbCellera and Vertex agree collaboration to develop multispecific T-cell engagers
Incyte's Opzelura approved in European Union for moderate atopic dermatitis